When news coverage mentions a generic drug maker "challenging" a patent on semaglutide or tirzepatide, it's almost always referring to a specific, formal legal step called a Paragraph IV certification. Understanding what that actually is makes patent-related drug news much easier to follow.
The Legal Framework Behind It
In the United States, generic drug approval runs through a law known as the Hatch-Waxman Act. Among other things, it created a streamlined approval pathway for generics, the Abbreviated New Drug Application, that lets a generic maker rely on the brand-name drug's existing safety and efficacy data rather than repeating full clinical trials, provided the generic is shown to be equivalent to the original.
The Four Certification Paths
As part of that abbreviated application, a generic manufacturer has to address any patents listed against the brand-name drug in the FDA's Orange Book (the subject of a separate guide on this site). The law gives the applicant four ways to do that, called Paragraph I through Paragraph IV certifications. Paragraph I says no relevant patents are listed. Paragraph II says the listed patents have already expired. Paragraph III says the applicant will wait until the listed patents expire before marketing. Paragraph IV is the aggressive option: it asserts that a listed patent is either invalid or won't be infringed by the generic product, and that the generic maker intends to market its product before that patent expires.
What Happens After a Paragraph IV Filing
Filing a Paragraph IV certification requires notifying the brand-name patent holder, who then has 45 days to sue for patent infringement. If they do, the law grants an automatic 30-month stay, during which the FDA generally won't give final approval to the generic application while the patent dispute plays out in court. That litigation can end in several ways: the generic maker can win, the patent holder can win, or, very commonly, the two sides can reach a settlement, sometimes including an agreed-upon date when the generic will be allowed to launch before the patent's full term ends.
The Reward for Being First
To encourage generic makers to take on this legal risk, the law offers the first company to file a successful Paragraph IV certification against a given patent a period of 180 days of exclusivity, during which no other generic version of that drug can enter the market. That exclusivity window is itself a valuable commercial prize, which is part of why multiple generic companies often race to file Paragraph IV challenges against the same lucrative drug at nearly the same time.
Why This Matters for GLP-1 Drugs
Semaglutide and tirzepatide are protected by patent portfolios that extend years into the future, which is a major reason true FDA-approved generic versions of these drugs remain years away, a topic covered in more detail in this site's news coverage of GLP-1 patent timelines. Paragraph IV filings, when they eventually happen against these drugs, will be one of the key events to watch for as an early signal of when generic competition might actually arrive.
The Bottom Line
A Paragraph IV certification is a specific legal claim, not just a generic company saying it disagrees with a patent, that starts a defined legal process with real deadlines and a real prize for whoever files first successfully. It's one of the main mechanisms, alongside patent expiration itself, by which brand-name drugs eventually face generic competition.